Findings seen for amphetamine/dextroamphetamine and methylphenidate exposure

Findings seen for unmedicated youths with anxiety disorder who have normalization over the course of treatment

Models that enable primary care practitioners to diagnose and evaluate patients for treatment eligibility would have biggest impact on wait times

No serious injuries related to the medication mix-up have been reported

Quit rate higher for ECs than nicotine replacement therapy; at six months, 62.8 percent in EC arm still using ECs

Increases seen in suicidal thoughts, depressive or anxiety symptoms, and inattention or hyperactivity

Small effects seen for improved fecal calprotectin and C-reactive protein

Symptoms of distress experienced by patients in palliative care are significantly reduced with FLOW-virtual reality therapy

11.63 percent of youth aged 5 to 24 years had mental disorders; 1.22 percent had substance use disorders in 2019